JOLED, a unit of JDI, which sold the first OLED screens this month, is the first in the world to adopt low-cost printing that will initially be available for medical devices.
The company is currently seeking financing, currently amounting to 100 billion yen to expand its production capacity.
It is reported that Sony and Panasonic are also expected to invest 50-100 billion yen JOLED each.In addition, Japan's Sumitomo Chemical and 斯库林 Group is also considering JOLED investment.Japanese media pointed out that these four companies will total investment in JOLED 200-400 billion.
OLED screen by virtue of more intelligence, more flexible, more colorful and other characteristics beyond the LCD screen, has been widely welcomed, but its high cost, preventing the popularization of the OLED screen.In the latest iPhone X smartphone, Apple first time Using the OLED screen.It is understood that JOLED inkjet printing process, compared with the mainstream of the evaporation mode of production costs can be reduced by about 30 to 50%.
A JOLED spokesman said the company is in talks with several materials and equipment manufacturers on investment matters, but the spokesman did not reveal more details.
A Denso spokesman said the company did not announce an investment in JOLED; a spokesman for Skurin denied that it was considering investing in JOLED; and Sony said it has not made a final decision yet, while Matsushita and Sumitomo Chemical declined to comment.
Founded in 2015, JOLED merged the OLED divisions of Sony and Panasonic.Among JOLED's ownership, 75% belongs to the Japan Innovation Network Fund, 15% to Japan Display, and Sony and Panasonic each own 5%.